Dazucorilant in Patients With Amyotrophic Lateral Sclerosis | MicrobiomeTrials← Back to trialsNCT05407324
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2022-11-15Est. Completion: 2026-10
Enrollment target: 279 participants Locations- 062, Phoenix, Arizona, United States
- 278, San Francisco, California, United States
- 287, Neptune City, New Jersey, United States
- 353, New York, New York, United States
- 108, Leuven, Belgium
- 425, Hamilton, Ontario, Canada
- 273, Montreal, Quebec, Canada
- 422, Bron, France
- 258, Lille, France
- 257, Limoges, France
- 261, Marseille, France
- 423, Montpellier, France
- 259, Nice, France
- 262, Paris, France
- 256, Tours, France
- 255, Berlin, Germany
- 270, Bonn, Germany
- 268, Dresden, Germany
- 260, Hanover, Germany
- 265, Jena, Germany
- 386, München, Germany
- 267, Rostock, Germany
- 269, Ulm, Germany
- 253, Dublin, Ireland
- 264, Utrecht, Netherlands
Other microbiome trials you might be interested in
Amyotrophic Lateral Sclerosis (ALS)Chronic Respiratory FailureNeuromuscular Disease PatientsNeuromuscular DiseaseRespiratory InsufficiencyRespiratory Insufficiency Requiring Mechanical VentilationPositive Pressure VentilationNon-invasive VentilationNon-invasive Ventilation SupportNon-invasive Ventilatory Support
Amyotrophic lateral sclerosis (ALS) is a disease that causes weakness of the muscles of the body. The disease can eventu…
Hershey, United StatesEst. completion May 2029
283, Bydgoszcz, Poland385, Krakow, Poland254, Warsaw, Poland274, Warsaw, Poland302, Barcelona, Spain115, Barcelona, Spain303, Madrid, Spain282, Málaga, Spain194, Valencia, Spain263, Stoke-on-Trent, United KingdomContactCorcept Therapeutics Incorporated
TERMINATED
Amyotrophic Lateral Sclerosis
The median survival of patients with amyotrophic lateral sclerosis (ALS) is 3 to 5 years and mortality is mainly related…
Montpellier, FranceCompleted Oct 21, 2025